Dr. Mier is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Beth Israel Med Center
330 Brookline Ave
Boston, MA 02215Phone+1 617-667-0430- Is this information wrong?
Education & Training
Emory University School of MedicineResidency, Internal Medicine, 1973 - 1975
Indiana University School of MedicineClass of 1973
Certifications & Licensure
MA State Medical License 1980 - 2021
GA State Medical License 1974 - 1977
Clinical Trials
- A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors Start of enrollment: 2012 Oct 01
- A Study of BBI503 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2012 Feb 01
- Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors Start of enrollment: 2017 Feb 28
Publications & Presentations
PubMed
- 2 citationsRapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitorsRohit Thummalapalli, Johannes C. Melms, James W. Mier, Benjamin Izar> ;Melanoma Research. 2020 Apr 1
- 291 citationsLenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial CancerVicky Makker, Matthew H. Taylor, Carol Aghajanian, Ana Oaknin, James W. Mier, Allen Lee Cohn, Margarita Romeo, Raquel Bratos, Marcia S. Brose, Christopher DiSimone, Ma...> ;Journal of Clinical Oncology. 2020 Mar 13
- 1 citationsRetraction: The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma CellsDavid J. Panka, Wei Wang, Michael B. Atkins, James W. Mier> ;Cancer Research. 2019 Oct 15
- Join now to see all
Press Mentions
DF/HCC Kidney Cancer Program Symposium 2016May 20th, 2016
Grant Support
- P4 - Treating The P13-Kinase/AktNational Cancer Institute2010–2011
- Targeting RAF In Melanoma: Mechanisms For Effect &Resistance &Opportunities ForNational Cancer Institute2008–2011
- Treating The P13-Kinase/AktNational Cancer Institute2009
- Phase I Clinical Trial Of Decitabine Prior To Dacarbazine In Advanced MelanomaNational Center For Research Resources2005–2006
- Core--Immune MonitoringNational Cancer Institute2001–2002
- Clinical Trials With IL12National Cancer Institute2001–2002
- In Vivo Effects Of IL 2--Role Of TNF And TNF R FamiliesNational Cancer Institute1997–1999
- Immunobiology Of LAK CellsNational Cancer Institute1997–1998
- Biological Effects Of Rhil-12National Cancer Institute1997–1998
- Immunobiology Of LAK CellsNational Cancer Institute1987–1996
- Immunobiology Of LAK CellsNational Cancer Institute1991–1993
- In Vivo Effects Of Recombinant Human InterleukinNational Cancer Institute1985–1987
Hospital Affiliations
Beth Israel Deaconess Medical CenterBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
